AIM ImmunoTech Expands Oncology IP Protection for Ampligen Through 2039

AIM ImmunoTech has been granted a broad U.S. patent covering the use of Rintatolimod (Ampligen) combined with Pembrolizumab (Keytruda), extending intellectual property rights for the oncology treatment.

31 Aug, 12:51 — 31 Aug, 12:51

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual3d ago

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - Taiwan News

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 Taiwan News

Read full article →

AIM ImmunoTech Expands Oncology IP Protection for Ampligen Through 2039

Sources

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - Taiwan News

Related Stories

UNICEF Report Finds 20 Million Children Annually Face Online Sexual Exploitation

Genetically Modified Pig Kidney Keeps US Patient Alive for Record Nine Months

Pentagon Temporarily Rescinds Testosterone Screening Guidance for Troops

RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally